Hepatitis B

Table of Contents

  1. Overview: A Vaccine-Preventable Cause of Liver Cancer
  2. Virology and Lifecycle: The cccDNA Reservoir
  3. Transmission and Risk Factors
  4. Phases and Natural History of Chronic HBV
  5. Serology Interpretation: Decoding HBV Blood Tests
  6. Diagnosis, Screening, and Monitoring
  7. Treatment with Antiviral Medications
  8. Hepatocellular Carcinoma: HBV's Most Feared Complication
  9. Vaccination: One of Medicine's Greatest Successes
  10. Special Populations and Co-infections
  11. Research Papers
  12. Connections
  13. Featured Videos

Overview: A Vaccine-Preventable Cause of Liver Cancer

Hepatitis B is a chronic liver infection caused by the hepatitis B virus (HBV) — an enveloped, partially double-stranded DNA virus belonging to the Hepadnaviridae family and the genus Orthohepadnavirus. It is one of the most common and consequential infectious diseases in human history: globally, an estimated 254 million people live with chronic HBV infection, and the virus kills approximately 820,000 people every year through cirrhosis and hepatocellular carcinoma (liver cancer). In the United States alone, approximately 2.4 million people are living with chronic HBV, many undiagnosed.

What sets hepatitis B apart from other viral hepatitides is a combination of features that makes it both highly dangerous and uniquely preventable. HBV is the world's leading infectious cause of hepatocellular carcinoma (HCC), responsible for 50–55% of all liver cancers globally — particularly in Asia and sub-Saharan Africa where perinatal and early childhood transmission created cohorts of chronically infected adults before vaccination programs existed. Unlike hepatitis C, HBV has a highly effective vaccine — one of the most successful ever developed — that provides lifelong protection in 95% of immunocompetent adults who receive the full series. And unlike hepatitis A, HBV can establish chronic infection in a large proportion of those it infects: up to 90% of infants infected at birth will develop chronic disease, compared to less than 5% of adults infected for the first time.

The most critical concept in understanding HBV's global burden is perinatal transmission — mother-to-child transmission at birth. This is by far the most important route for chronic infection worldwide. An infant born to a mother with high HBV replication who does not receive timely vaccine and immune globulin has a 70–90% chance of developing chronic HBV. When infection occurs at birth, the newborn's immature immune system largely tolerates the virus rather than clearing it, establishing a chronic carrier state that can persist for life and lead to cirrhosis and liver cancer decades later.

The medical story of HBV is also defined by what current treatments cannot do. Effective antiviral drugs — primarily tenofovir and entecavir — can suppress HBV replication to undetectable levels, normalize liver inflammation, and dramatically reduce the risk of cirrhosis and cancer. But they cannot eliminate the virus. HBV's DNA integrates into host liver cell chromosomes and also maintains a nuclear reservoir called covalently closed circular DNA (cccDNA) that persists inside hepatocyte nuclei indefinitely, beyond the reach of any approved antiviral. This is why the goal of most HBV treatment is viral suppression, not cure — and why lifelong therapy is usually required. "Functional cure" (loss of HBsAg from the blood) occurs in fewer than 10% of treated patients per year, and even then the cccDNA reservoir remains. The development of agents capable of silencing or eliminating cccDNA is the defining frontier of HBV research.

Back to Table of Contents

Virology and Lifecycle: The cccDNA Reservoir

Understanding HBV's unique biology explains both its exceptional tenacity and why cure remains elusive. The virus has evolved an ingenious molecular strategy for persistence within the liver.

HBV Structure

HBV is a small virus (~42 nm) consisting of an outer lipid envelope studded with three surface glycoproteins — the large (L), middle (M), and small (S) forms of hepatitis B surface antigen (HBsAg). Inside the envelope sits an icosahedral nucleocapsid containing the hepatitis B core antigen (HBcAg), the viral DNA polymerase (which also functions as a reverse transcriptase), and the viral genome: a unique, partially double-stranded circular DNA molecule approximately 3.2 kilobases in length — one of the smallest genomes of any animal virus.

The Viral Genome: Four Overlapping Reading Frames

Despite its tiny size, the HBV genome encodes four overlapping open reading frames, making extraordinarily efficient use of its DNA:

The Life Cycle: Entry, Reverse Transcription, and cccDNA

HBV's lifecycle is unusual among DNA viruses because it involves a reverse transcription step, giving it some similarities to retroviruses:

  1. Entry — HBV binds to the sodium taurocholate cotransporting polypeptide (NTCP) receptor on the surface of hepatocytes — the liver-specific receptor that explains HBV's strict tropism for liver cells. After endocytosis, the nucleocapsid is released into the cytoplasm.
  2. cccDNA formation — the relaxed circular DNA (rcDNA) genome is transported to the nucleus, where cellular repair enzymes convert it into covalently closed circular DNA (cccDNA). This minichromosome is organized around histones in an episomal (non-integrated) form. It is the master template for all HBV mRNA transcription and the molecular explanation for HBV's persistence. Current antiviral drugs have no direct activity against cccDNA.
  3. Transcription — cccDNA is transcribed by host RNA polymerase II into multiple mRNAs, including pregenomic RNA (pgRNA), which serves as both the mRNA for core and polymerase proteins and the template for reverse transcription.
  4. Reverse transcription and packaging — pgRNA is encapsidated with the viral polymerase into new core particles, where the polymerase reverse-transcribes pgRNA into new rcDNA genomes. New virions are assembled and secreted, or recycled back to the nucleus to amplify the cccDNA pool.
  5. Chromosomal integration — a separate but important process: HBV DNA also integrates into random sites in host hepatocyte chromosomes. Unlike cccDNA, integrated HBV cannot produce new virions but continues to produce HBsAg (contributing to the immune-evasive HBsAg excess) and drives HCC through insertional mutagenesis and HBx protein expression, even in patients classified as "inactive carriers."

Immune Pathogenesis: The Liver Damages Itself

An important and counterintuitive fact: HBV is not directly cytopathic. The virus itself does not kill liver cells. Instead, almost all liver damage in HBV infection is caused by the host immune response — specifically cytotoxic CD8+ T lymphocytes (killer T cells) that recognize HBV-derived peptides presented on the surface of infected hepatocytes and destroy those cells. In acute self-limited HBV, this robust immune response eliminates infected cells (causing the transient hepatitis) and clears the infection. In chronic HBV, the T cell response is exhausted, functionally impaired, and unable to clear the infection, but still active enough to cause ongoing low-grade (or occasionally high-grade) liver inflammation and fibrosis. ALT flares in chronic HBV reflect surges in immune activity against HBV-infected cells.

Back to Table of Contents

Transmission and Risk Factors

HBV is transmitted through exposure to infected blood, semen, vaginal secretions, and other body fluids. It is not spread through food, water, casual contact, coughing, sneezing, or sharing utensils. Understanding the distinct routes of transmission is essential because they vary dramatically by geography and explain why HBV's epidemiology looks so different in different parts of the world.

Perinatal / Vertical Transmission

This is the most epidemiologically important route globally. Transmission occurs primarily during labor and delivery — through exposure to maternal blood and body fluids — rather than transplacentally in most cases. Key facts:

Sexual Transmission

The most common route of new HBV infections in the United States. HBsAg is present in semen and vaginal secretions at high concentrations. Key points:

Blood-Borne Transmission

Horizontal Transmission in Childhood (Endemic Regions)

In high-endemic countries (especially parts of sub-Saharan Africa and Asia), significant HBV transmission occurs between young children — through minor skin breaks, shared toothbrushes or razors, contact with open wounds, and possibly saliva. This "horizontal" childhood transmission extends beyond vertical perinatal routes and explains ongoing high prevalence in endemic areas even with some maternal vaccination programs. It strongly motivates universal infant vaccination (not just vaccination of infants of HBsAg-positive mothers).

Other Routes

Back to Table of Contents

Phases and Natural History of Chronic HBV

The natural history of chronic HBV is among the most complex in all of hepatology. The virus and host immune system exist in a dynamic, shifting relationship that evolves over decades. The field has moved away from older "active" vs. "inactive" labeling — which was confusing and inaccurate — toward a five-phase model based on measurable parameters: HBsAg, HBeAg, HBV DNA, and ALT.

Understanding these phases matters for two reasons: they determine whether treatment is needed now, and they predict long-term outcomes including fibrosis and cancer risk. A single lab snapshot may not fully characterize a patient's phase — serial measurements over months may be needed.

Phase 1 — HBeAg-Positive Chronic Infection (formerly "Immune Tolerant")

Typically seen in perinatally-infected individuals and young adults from endemic areas. Characteristics:

Despite minimal current liver inflammation, patients are not without risk: HBV integration into host DNA is ongoing, HCC can rarely develop even in this phase over long time frames, and immune activity can emerge at any point.

Phase 2 — HBeAg-Positive Chronic Hepatitis (formerly "Immune Active" or "Immune Clearance")

The immune system mounts a meaningful attack on HBV-infected hepatocytes. This phase may emerge spontaneously or after years in Phase 1:

Some patients will undergo HBeAg seroconversion — loss of HBeAg and development of anti-HBe — which represents partial immune control. This can happen spontaneously (more commonly in patients with significant ALT elevation) or in response to antiviral treatment.

Phase 3 — HBeAg-Negative Chronic Infection (formerly "Inactive Carrier")

Following HBeAg seroconversion, many patients enter a quiescent phase:

Regular monitoring (every 6–12 months) is still required — even in apparent Phase 3 — because HBV DNA can fluctuate and patients can shift phases. The label "inactive carrier" is misleading precisely because the state is not necessarily permanent.

Phase 4 — HBeAg-Negative Chronic Hepatitis (formerly "Reactivation")

This phase arises in patients who have undergone HBeAg seroconversion but have HBV variants — most commonly precore stop codon mutations (G1896A) or basal core promoter (BCP) mutations — that allow active viral replication without producing HBeAg. This is increasingly recognized as common, particularly in genotype D infections (prevalent in Mediterranean, Middle East, South Asian populations):

The critical distinction between Phase 3 and Phase 4 is the HBV DNA and ALT level — not the HBeAg/anti-HBe pattern, which looks the same in both. This underscores why quantitative HBV DNA testing is essential in all chronic HBV patients.

Phase 5 — HBsAg Loss ("Functional Cure")

The most favorable outcome of chronic HBV is HBsAg seroconversion — the disappearance of HBsAg from the blood, sometimes accompanied by the development of anti-HBs antibodies. This is called "functional cure" because:

Spontaneous HBsAg loss occurs at a rate of roughly 1–3% per year in Phase 3 patients in high-income countries. Treatment with PEG-IFN has higher rates of HBsAg loss than nucleos(t)ide analogues, which rarely achieve this endpoint.

Back to Table of Contents

Serology Interpretation: Decoding HBV Blood Tests

HBV serology is notoriously confusing — even experienced clinicians sometimes misread the pattern. The key is understanding what each marker specifically tests for and then reading them as a set, not individually.

The Six Core Markers

HBsAg (Hepatitis B Surface Antigen) — the most important single screening marker. HBsAg is the protein coat of HBV. Its presence in blood means the virus is present — you are either acutely or chronically infected. If HBsAg persists beyond 6 months, the infection is chronic. HBsAg disappears after recovery from acute hepatitis B.

Anti-HBs (Antibody to Surface Antigen) — the protective antibody. Its presence means immunity, whether from successful vaccination or from recovery after natural infection. A level ≥10 mIU/mL is considered protective. Vaccination produces anti-HBs without ever producing anti-HBc — this is what distinguishes a vaccinated person from someone who had natural infection and recovered.

Anti-HBc IgM (Core Antibody, IgM Class) — the marker of acute HBV infection. IgM anti-HBc rises sharply after acute exposure and gradually falls over months. High-titer IgM anti-HBc = acute hepatitis B. Low-level IgM anti-HBc may also appear transiently during flares of chronic HBV.

Anti-HBc Total (Core Antibody, IgG Class) — the marker of prior or current natural exposure to HBV. Once infected, this antibody persists for life — even after complete recovery. It is NOT produced by vaccination. This marker is critical for two clinical scenarios: (1) identifying people with resolved past infection, and (2) flagging "isolated anti-HBc" patterns (discussed below).

HBeAg (Hepatitis B e Antigen) — a secreted protein derived from the precore region of the HBV genome. Its presence indicates high viral replication and high infectivity. HBeAg is positive in Phases 1 and 2 of chronic infection. Its disappearance (with or without anti-HBe development) is called "e antigen seroconversion" and represents a partial immune response milestone — though importantly, viral replication often continues at lower levels even after HBeAg loss.

Anti-HBe (Antibody to e Antigen) — appears after HBeAg seroconversion. Does NOT mean the patient is non-infectious or non-replicating — HBeAg-negative hepatitis (Phase 4) is defined by ongoing active replication despite anti-HBe positivity. Anti-HBe simply means HBeAg has been cleared.

HBV DNA (Viral Load) — the most sensitive and direct measure of viral replication. Quantified by PCR and reported in IU/mL. This is the single most important number for treatment decisions and monitoring treatment response. The goal of antiviral therapy is undetectable HBV DNA by sensitive PCR assay.

Key Interpretation Patterns

HBsAg Anti-HBc Anti-HBs HBeAg Interpretation
Positive Positive (IgM high) Negative Positive Acute hepatitis B (early, high replication)
Positive Positive Negative Positive Chronic HBV, Phases 1 or 2 (high replication)
Positive Positive Negative Negative (anti-HBe +) Chronic HBV, Phase 3 or 4 — check HBV DNA and ALT to distinguish
Negative Positive Positive Negative Resolved past infection — immune, no longer infectious
Negative Negative Positive Negative Successfully vaccinated — immune, never naturally infected
Negative Positive Negative Negative Isolated anti-HBc — see below
Negative Negative Negative Negative Never infected, not immune — vaccinate

The "Isolated Anti-HBc" Pattern

One of the most clinically important and underappreciated patterns: anti-HBc positive, HBsAg negative, anti-HBs negative. This can mean:

  1. Resolved past infection where anti-HBs has waned below detectable levels with time — the most common explanation in low-endemic settings.
  2. False-positive anti-HBc — can occur, especially in certain immunological conditions.
  3. Occult HBV infection — HBV DNA detectable by sensitive PCR in liver tissue or serum despite undetectable HBsAg — the most clinically significant possibility; affects approximately 15–20% of people with isolated anti-HBc in high-endemic settings.

The clinical significance of isolated anti-HBc is highest in the setting of immunosuppression: people with this pattern who receive rituximab, chemotherapy, or other potent immunosuppressives can experience HBV reactivation — sometimes severe or fatal. All patients being considered for significant immunosuppression should be tested for both HBsAg AND total anti-HBc.

Back to Table of Contents

Diagnosis, Screening, and Monitoring

Most people with chronic HBV have no symptoms for years or decades. Diagnosis depends on proactive screening, and ongoing management requires structured monitoring of viral activity, liver function, and cancer risk.

Who Should Be Screened

The US Preventive Services Task Force (USPSTF) recommends screening adults aged 18–79 at increased risk for HBV. High-risk groups include:

Initial Workup for Newly Diagnosed HBsAg-Positive Patients

Once HBsAg is confirmed positive, a comprehensive initial evaluation includes:

HDV Co-infection: Do Not Miss It

Hepatitis D virus (HDV) — the "delta virus" — is an incomplete RNA virus that can only replicate in the presence of HBV, because it uses HBsAg to form its own envelope. HDV testing (anti-HDV) is recommended in all HBsAg-positive patients who are at higher risk: persons who inject drugs, immigrants from high-HDV regions (Mongolia, Romania, Pakistan, parts of Africa), persons with rapidly progressive liver disease, or those with unexplained ALT elevation despite low HBV DNA. HDV co-infection accelerates cirrhosis dramatically and has a unique treatment (bulevirtide, approved in Europe; PEG-IFN).

Ongoing Monitoring in Chronic HBV

Even patients not yet on treatment require regular monitoring — because phase transitions can occur, and because HCC can arise without warning:

Unlike hepatitis C, HCC surveillance is recommended even in non-cirrhotic HBV patients who meet the above criteria, reflecting HBV's ability to cause cancer through chromosomal integration independently of cirrhosis.

Back to Table of Contents

Treatment with Antiviral Medications

The goals of HBV treatment are to suppress viral replication to undetectable levels, normalize liver inflammation (ALT), prevent progression to cirrhosis and hepatocellular carcinoma, and — in the small minority of patients who achieve it — accomplish HBsAg loss (functional cure). Current treatments accomplish the first three goals reliably; the fourth remains rare with available drugs.

Who Needs Treatment

Not every person with chronic HBV needs to start treatment immediately. Current AASLD 2018 guidelines (the most widely used in North America) recommend treatment for:

Patients in Phase 1 (HBeAg-positive, normal ALT, high DNA) and Phase 3 (HBeAg-negative, normal ALT, low DNA) are generally monitored rather than treated, because the risk-benefit ratio of lifelong antiviral therapy is less clearly favorable in the absence of active liver inflammation — though this remains an area of ongoing clinical debate.

Preferred First-Line Nucleos(t)ide Analogues

The foundation of HBV treatment is oral nucleos(t)ide analogues (NAs) that inhibit the HBV DNA polymerase/reverse transcriptase. Three agents have high barriers to resistance and are preferred:

Tenofovir alafenamide (TAF; brand name Vemlidy, 25 mg once daily) — the newest preferred first-line agent. TAF delivers tenofovir to hepatocytes more efficiently than the older TDF formulation, allowing a much lower dose with equivalent antiviral efficacy but substantially better renal and bone safety profile. TAF is preferred for most patients in the current guidelines, particularly those with renal impairment or osteoporosis risk. Data in pregnancy are more limited than for TDF.

Tenofovir disoproxil fumarate (TDF; brand name Viread, 300 mg once daily) — the older tenofovir formulation with an excellent 15+ year track record. Equally effective to TAF in suppressing HBV; higher barrier to resistance than entecavir in lamivudine-experienced patients. Associated with modest reductions in bone mineral density and renal function over time (mostly clinically insignificant, but relevant in those at baseline risk). TDF is the preferred antiviral in pregnancy based on extensive safety data from HIV treatment programs.

Entecavir (ETV; brand name Baraclude, 0.5 mg once daily in treatment-naive patients; 1 mg once daily in lamivudine-resistant patients) — a guanosine analogue with high potency and an excellent resistance profile in treatment-naive patients (resistance develops in <1% over 5 years). Long-term data demonstrate effective viral suppression and fibrosis regression comparable to tenofovir. Entecavir has a theoretical concern from in vitro cell-line studies about HCC promotion, but multiple large clinical studies have not confirmed this in humans, and it remains a standard first-line option. Entecavir is not preferred in pregnancy due to limited safety data and animal teratogenicity signals at high doses.

Agents to Avoid

Three older nucleoside analogues are now considered suboptimal and should not be used as first-line therapy:

Pegylated Interferon Alpha (PEG-IFN): The Finite-Course Option

PEG-IFN is fundamentally different from the NAs: it is an immune modulator rather than a direct antiviral. Given as weekly subcutaneous injections for 48 weeks, it has a higher rate of HBeAg seroconversion and HBsAg loss in selected responders than NAs, and offers the advantage of a finite treatment duration — no lifelong commitment. These are its main attractions.

The drawbacks are significant: flu-like symptoms (fever, fatigue, myalgia), cytopenia (low white cells and platelets), depression, thyroid abnormalities, and the need for weekly injections. PEG-IFN is contraindicated in patients with decompensated cirrhosis, autoimmune conditions, severe psychiatric illness, or pregnancy. The best candidates are younger non-cirrhotic patients with HBeAg-positive disease, elevated ALT, and — for genotype-A infections — a favorable baseline HBsAg level. Quantitative HBsAg kinetics at 12 and 24 weeks help predict response: patients who fail to show HBsAg decline typically do not benefit from continuing treatment.

Duration and Treatment Goals

For most patients on NAs, treatment is lifelong. Stopping therapy in patients who have not achieved HBeAg seroconversion or HBsAg loss typically results in virological relapse — the rebound of HBV DNA — often accompanied by ALT flares that can be severe. For HBeAg-positive patients who achieve durable HBeAg seroconversion on NA therapy (confirmed on repeat testing after at least 12 months of consolidation), some guidelines allow cautious discontinuation of NA therapy with close monitoring. Patients who achieve HBsAg loss can generally stop treatment, with ongoing surveillance for late HBsAg reappearance, especially if immunosuppression is ever contemplated.

Back to Table of Contents

Hepatocellular Carcinoma: HBV's Most Feared Complication

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide, and HBV is responsible for approximately 50–55% of all HCC cases globally — a proportion that rises to over 70% in parts of East Asia and sub-Saharan Africa. HCC from HBV is one of medicine's clearest examples of an infection that drives cancer through distinct and well-understood molecular mechanisms.

Why HBV Causes Liver Cancer: Mechanisms

HBV causes HCC through multiple interacting mechanisms:

The consequence of the integration and HBx mechanisms is that HCC can develop in non-cirrhotic livers in HBV — a stark difference from HCV-related HCC, which almost always requires cirrhosis. This is why HCC surveillance guidelines for HBV extend to non-cirrhotic patients meeting certain criteria, whereas HCV surveillance is generally limited to those with established cirrhosis.

Risk Factors for HCC in HBV

How Antiviral Treatment Reduces HCC Risk

One of the most important benefits of HBV antiviral therapy is cancer prevention. Multiple large studies have demonstrated that achieving viral suppression with NAs or PEG-IFN reduces HCC incidence by 60–80% in treated patients compared to historical untreated controls or concurrent untreated cohorts. However, HCC risk is not eliminated — it continues at a lower rate, particularly in patients who already had advanced fibrosis or cirrhosis before treatment. This residual risk is why HCC surveillance must continue even after years of successful antiviral therapy, indefinitely for cirrhotic patients and per guidelines for non-cirrhotic patients who meet surveillance criteria.

Surveillance Protocol and Diagnosis

Standard surveillance: liver ultrasound every 6 months, with or without serum AFP (alpha-fetoprotein). AFP alone misses a significant proportion of HCC (many HCC tumors do not elevate AFP) and has poor specificity (AFP is elevated in active HBV hepatitis without cancer), so it is used as an adjunct to ultrasound, not a replacement. If ultrasound reveals a liver nodule, the diagnostic pathway follows the LI-RADS (Liver Imaging Reporting and Data System) classification using multiphasic CT or MRI with contrast — most HCC has characteristic arterial enhancement and portal-phase washout that allows non-biopsy diagnosis. LI-RADS 5 observations are treated as HCC without biopsy in the appropriate clinical context.

Back to Table of Contents

Vaccination: One of Medicine's Greatest Successes

The hepatitis B vaccine is among the most effective vaccines ever developed and stands as a remarkable public health achievement. It is a recombinant subunit vaccine — it contains only a purified form of the HBsAg protein produced by yeast, with no live virus, no blood products, and no ability to cause HBV infection. It is safe for immunocompromised individuals, infants, pregnant women, and the elderly.

Available Vaccine Formulations

The Birth Dose: Preventing the Most Dangerous Exposures

The universal birth-dose recommendation — giving the first hepatitis B vaccine to all infants within 24 hours of birth — is one of the most impactful single vaccine policies in existence. For infants born to HBsAg-positive mothers, the birth dose is combined with hepatitis B immune globulin (HBIG, 0.5 mL IM at a different site), both given within 12 hours of birth. This combination provides both passive immunity (HBIG antibodies) and active immunization (vaccine stimulating the infant's own immune response), reducing perinatal HBV transmission by 85–95%. For infants born to HBsAg-negative mothers, the birth dose alone (no HBIG needed) still provides important protection against horizontal childhood transmission and establishes early immunity before potential exposures.

Post-Vaccination Serology Testing

Routine post-vaccination testing for anti-HBs is not recommended for the general population — most respond well and the result doesn't change management. However, testing 1–2 months after completing the vaccine series is recommended for healthcare workers, dialysis patients, and sexual or household contacts of HBsAg-positive individuals — groups where knowing the immune status directly affects clinical decisions. A confirmed protective response (anti-HBs ≥10 mIU/mL) is considered durable in immunocompetent individuals — memory B cells persist even after anti-HBs levels decline below detectable thresholds, providing anamnestic protection. Booster doses are not routinely recommended for immunocompetent adults who responded to the initial series.

Non-Responders

Approximately 5–10% of healthy adults do not develop adequate anti-HBs after a 3-dose series. Non-response is more common with increasing age, obesity, smoking, immunocompromise, and male sex. Non-responders should receive a second complete 3-dose series (or Heplisav-B series) — approximately 50% of initial non-responders will respond to a second series. Switching to PREHEVBRIO (3-antigen vaccine) is an option for persistent non-responders. After two complete series, true non-responders should be tested for HBsAg and anti-HBc to rule out pre-existing HBV infection, and should be counseled about remaining unprotected.

Post-Exposure Prophylaxis

For unvaccinated persons with significant HBV exposure (needlestick from HBsAg-positive source, sexual contact with HBsAg-positive person, neonates of HBsAg-positive mothers), HBIG plus immediate initiation of the HBV vaccine series provides passive-active prophylaxis. HBIG must be given as soon as possible — within 24 hours for sexual exposure, within 12 hours for neonates. For vaccinated individuals with documented anti-HBs response, no additional treatment is needed after exposures.

Back to Table of Contents

Special Populations and Co-infections

Certain patient populations with chronic HBV require modified clinical approaches because of interactions between HBV, comorbid conditions, medications, or physiological states.

Pregnancy

Hepatitis B management in pregnancy requires a coordinated approach between hepatologist, obstetrician, and neonatologist:

HIV Co-infection

HBV-HIV co-infection affects approximately 5–10% of HIV-positive individuals in high-income countries and significantly more in sub-Saharan Africa. Key management principles:

Immunosuppression and HBV Reactivation

HBV reactivation is a life-threatening complication of immunosuppressive therapy in patients with chronic or resolved HBV. The risk varies by the type of immunosuppression and the patient's HBV serological status:

The standard approach: screen ALL patients for HBsAg and anti-HBc before starting immunosuppressive therapy. HBsAg-positive patients should receive prophylactic antiviral therapy (tenofovir or entecavir) starting before immunosuppression and continuing for 6–12 months after its completion (longer for rituximab-based regimens). Anti-HBc-positive/HBsAg-negative patients receiving high-risk immunosuppression should receive either prophylaxis or very close monitoring with HBsAg and HBV DNA every 1–3 months. The mortality of unrecognized and untreated HBV reactivation in this setting is up to 25%.

Dialysis Patients

Hemodialysis patients face elevated HCC risk from chronic HBV and have reduced immune responses to vaccination. Key considerations:

Hepatitis D Virus (HDV) Co-infection

HDV co-infection represents the most severe form of viral hepatitis. HDV is a defective RNA satellite virus — it can only infect individuals who are already infected with HBV, because HDV uses HBsAg as the protein coat for its own viral envelope. Key facts:

Back to Table of Contents

Research Papers

  1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403. PMID 29599078. DOI: 10.1016/S2468-1253(18)30056-6
  2. Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67:1560–1599. PMID 29405329. DOI: 10.1002/hep.29800
  3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. PMID 16391218. DOI: 10.1001/jama.295.1.65
  4. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B. Lancet. 2005;365:123–129. PMID 15639293. DOI: 10.1016/S0140-6736(05)17701-0
  5. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455. PMID 19052126. DOI: 10.1056/NEJMoa0802878
  6. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010. PMID 16525137. DOI: 10.1056/NEJMoa051285
  7. Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63:284–306. PMID 26566246. DOI: 10.1002/hep.28280
  8. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527. PMID 12029638. DOI: 10.1053/jhep.2002.33638
  9. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82:967–975. PMID 17673066. DOI: 10.4065/82.8.967
  10. Innes H, Dewar D, Hutchinson SJ, et al. Quantitative hepatitis B surface antigen kinetics as a predictor of hepatitis B surface antigen loss after treatment with pegylated interferon. Gut. 2016;65:154–161. PMID 25539671. DOI: 10.1136/gutjnl-2014-308560
  11. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016–2021. Geneva: WHO; 2016. URL: WHO Publication WHO-HIV-2016.06
  12. Bui TTT, Dao DY, Kim WR. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2013;7:519–530. PMID 26202186. DOI: 10.1007/s12072-013-9440-9

PubMed Topic Searches

  1. Hepatitis B antiviral treatment outcomes
  2. HBV cccDNA persistence and cure research
  3. HBV hepatocellular carcinoma risk and surveillance
  4. HBV vaccination immunogenicity and birth dose
  5. HBV natural history and phase transitions
  6. HBV reactivation and immunosuppression

Back to Table of Contents

Connections

Back to Table of Contents